Russia-Ukraine tensions could be amplified by the arrival of U.S. security aid in Kyiv

Reuters

Alzheimer’s patient groups protest U.S. Medicare coverage proposal limiting use of new drugs

Alzheimer’s patient groups, disappointed by Medicare’s plan to sharply limit coverage of new drugs for the brain-wasting disease, are planning publicity and lobbying campaigns to protest a proposal they say could delay their use for 10 years. “Congress has to know how bad this will be for patients,” said John Dwyer, president of Global Alzheimer’s Platform Foundation (GAP) advocacy group. In a preliminary decision https://www.reuters.com/business/healthcare-pharmaceuticals/future-biogens-aduhelm-hinges-us-medicare-alzheimers-coverage-2022-01-11 last week, the U.S. Centers for Medicaid and Medicare Services (CMS), which runs the government health plan for people age 65 and older, said it would cover Biogen Inc’s already approved Aduhelm, and similar Alzheimer’s disease treatments in development, only for patients enrolled in approved clinical trials.